No attachments available.
2-PAM Autoinjectors Project Bioshield
Contact and place of performance
Erin Greninger, Contracting Officer
Washington, DC 20024
USA
This is a presoliciation notice for the following:
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.
The Administration for Strategic Preparedness and Response (ASPR) has issued this presolicitation under solicitation number 75A50126R00002 for the 2-PAM Autoinjectors Project Bioshield. The Biomedical Advanced Research and Development Authority (BARDA) seeks the late-stage clinical development and regulatory approval of 2-PAM autoinjectors as a drug-device combination product. This initiative addresses the treatment of organophosphate poisoning, including nerve agents, for both adult and pediatric populations. Following regulatory approval, the project includes the procurement of these autoinjectors for the Strategic National Stockpile (SNS) and the CHEMPACK Program.
Work for this requirement is classified under NAICS 541714, Research and Development in Biotechnology (except Nanobiotechnology), and PSC AB12, Community and Regional Development R&D Services; Community Development; Applied Research. There is no set-aside designated for this opportunity. Performance is located in Washington, DC, and the point of contact is Contracting Officer Erin Greninger.
The response deadline for this notice is June 16, 2026. This federal opportunity was published and last updated on June 2, 2026, with zero attachments currently associated with the notice on SAM.gov.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.